Truist Securities Reiterates Buy on Bristol-Myers Squibb

بريستول مايرز سكويب كو

Bristol-Myers Squibb Company

BMY

0.00

Truist Securities analyst Robyn Karnauskas reiterates Bristol-Myers Squibb (NYSE: BMY) with a Buy.